Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 180

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 180
---
 net zero emissions requirements. The cost of compliance with these laws and regulations and the cost to secure such insurance coverage may become significant in the future, and any failure to comply may result in substantial fines and other business and reputational consequences, any of which could negatively affect our business, financial condition, results of operations or growth prospects. We could be adversely affected by violations of the FCPA and other anti -bribery laws. We are subject to various anti -briberylaws, including the U.S. Foreign Corrupt Practices Act (“FCPA”), and similar anti -briberylaws in the non -U.S. jurisdictions in which we operate. The FCPA prohibits companies and their intermediaries from making payments in violation of law to non -U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. These laws are complex and far -reachingin nature, and we may be required in the future to alter one or more of our practices to be in compliance with these laws or any changes to these laws or their interpretation. We currently conduct a significant portion of our business outside the United States. These operations could involve dealings with governments, foreign officials and state -ownedentities, such as government hospitals, outside the United States. We also may use independent distributors to sell our products internationally. Any such third parties could be deemed to be our agents and we could be held responsible for any corrupt or other illegal activities of our employees or these third parties. Any violations of these laws or allegations of such violations could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and result in a material adverse effect on our business, prospects, financial condition or results of operations. Additionally, other U.S. companies in the medical device and pharmaceutical fields have faced substantial fines and criminal penalties for violating the FCPA and we could incur the same if we violate the FCPA or other applicable anti -briberylaws. 68 Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. Our operations involve the use and disclosure of personal and business information that could be used to impersonate third parties or otherwise gain access to their data or funds. As such, we are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional,